Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Luke Discusses Noncutaneous Melanoma

March 1st 2018

Jason J. Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses noncutaneous melanoma.

Dr. Andtbacka Discusses the Role of T-VEC in Melanoma

February 24th 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Obesity Linked to Improved Outcomes in Men With Metastatic Melanoma

February 22nd 2018

Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI.

Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma

February 21st 2018

The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.

Dr. Sullivan on Targeted Therapy for BRAF-Mutant Melanoma

February 20th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses novel molecular targets in patients with melanoma.

Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma

February 19th 2018

The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.

Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma

February 17th 2018

Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma.

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

February 15th 2018

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration

February 15th 2018

Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.

Focus Moves to Earlier Settings in Melanoma

February 12th 2018

Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy.

Updates in Targeted Combination Therapies for Melanoma

February 9th 2018

With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.

Binimetinib/Encorafenib Positive OS Data Released as FDA Weighs Melanoma Approval

February 6th 2018

Treatment with encorafenib and binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

Complete Lymph Node Dissection Not Superior to Surveillance in Melanoma

January 31st 2018

Daniel Coit, MD, discusses clinical findings with complete lymph node dissection and the evolution of surgery in the melanoma landscape.

Novel Combinations Continue to Advance Melanoma Field

January 29th 2018

Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.

Weber Shares Insight on Future of Immunotherapy in Melanoma

January 26th 2018

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

Dr. Coit on the Evolving Role of Surgery in Patients With Melanoma

January 25th 2018

Daniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.

Dr. Kluger on Systemic Management of Melanoma With Brain Metastases

January 25th 2018

Harriet Kluger, MD, professor of medicine, associate cancer center director for education and training, deputy section chief, Medical Oncology, Yale Cancer Center, discusses the progression of treatment for patients with melanoma who have brain metastases.

CMV Vaccine Falls Short in Phase III Trial

January 23rd 2018

ASP0113, an investigational DNA vaccine developed for cytomegalovirus-seropositive hematopoietic stem cell transplant patients, has failed to meet its primary and secondary endpoints.

Ipilimumab Approved in Europe for Pediatric Melanoma

January 23rd 2018

Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

January 17th 2018

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.